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Sensitivity to angiotensin II dose in patients 
with vasodilatory shock: a prespecified analysis 
of the ATHOS-3 trial
Kealy R. Ham1*, David W. Boldt2, Michael T. McCurdy3, Laurence W. Busse4, Raphael Favory5,6, Michelle N. Gong7, 
Ashish K. Khanna8, Stefan N. Chock9, Feng Zeng10, Lakhmir S. Chawla10, George F. Tidmarsh10 
and Marlies Ostermann11
Abstract 
Background: Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of 
angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg−1 min−1 
angiotensin II at 30 min (≤ 5 ng kg−1 min−1 subgroup) to maintain mean arterial pressure (MAP) ≥ 75 mmHg versus 
patients receiving > 5 ng kg−1 min−1 angiotensin II at 30 min (> 5 ng kg−1 min−1 subgroup). Data from angiotensin 
II-treated patients enrolled in the ATHOS-3 trial were used.
Results: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg−1 min−1 at treat-
ment initiation to ≤ 5 ng kg−1 min−1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II 
levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg−1 min−1 subgroup 
(84/163). Patients in the ≤ 5 ng kg−1 min−1 subgroup were more likely to have a MAP response at 3 h versus those 
in the > 5 ng kg−1 min−1 subgroup (90% vs. 51%, respectively; odds ratio, 8.46 [95% CI 3.63–19.7], P < 0.001). Day 28 
survival was also higher in the ≤ 5 ng kg−1 min−1 subgroup versus the > 5 ng kg−1 min−1 subgroup (59% vs. 33%, 
respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], P = 0.0007); multivariate analyses supported the survival benefit 
in patients with lower angiotensin II levels. The ≤ 5 ng kg−1 min−1 subgroup had a more favorable safety profile and 
lower treatment discontinuation rate than the > 5 ng kg−1 min−1 subgroup.
Conclusions: This prespecified analysis showed that down-titration to ≤ 5 ng kg−1 min−1 angiotensin II at 30 min is 
an early predictor of favorable clinical outcomes which may be related to relative angiotensin II insufficiency.
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© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Shock is characterized by inadequate organ perfusion, 
which, if not rapidly corrected, leads to multiorgan fail-
ure and death [1]. International guidelines recommend 
catecholamines as first-line vasopressor agents [2, 3]. 
Outcomes remain unacceptable because approximately 
half of patients with vasodilatory shock do not survive 
beyond 28  days [4–7]. Additionally, treatment with 
norepinephrine may cause immunosuppression and 
seriously complicate the clinical course in patients with 
septic shock, the most common form of shock [8, 9]. 
High-dose catecholamines are associated with worse 
outcomes and adverse events in patients who require 
higher doses to achieve targeted hemodynamic param-
eters [9, 10]. An alternative noncatecholamine agent, 
vasopressin [3], is effective in some patients and may 
allow the lowering of catecholamine dose, but it has 
not been shown to improve survival [3]. Further, fewer 
than 50% of patients in shock generate a blood pres-
sure response to treatment with vasopressin [11], and 
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vasopressin may cause cardiac toxicity, heart failure, 
and mesenteric ischemia at higher doses [3, 12].
Angiotensin II is a naturally occurring peptide with 
strong vasopressor activity [13]. A pilot study indicated 
that the addition of synthetic human angiotensin II to 
catecholamine and vasopressin therapy maintained 
mean arterial pressure (MAP) in patients with vasodila-
tory shock, while allowing for a reduction in catecho-
lamine dosing [14]. In addition, the pilot study noted 
that 20% of treated patients were exquisitely sensitive 
to angiotensin II. Given the risk of higher-dose cat-
echolamines, the ability to approach or restore nor-
mal hemodynamic function with low doses of systemic 
vasopressor(s) is an important clinical goal.
Following the pilot study, the randomized, double-
blind, phase 3 Angiotensin II for the Treatment of 
High-Output Shock (ATHOS-3) trial (ClinicalTrials.
gov, NCT02338843) demonstrated that angiotensin II 
significantly increased MAP and provided a catecho-
lamine-sparing effect versus placebo in patients with 
catecholamine-resistant vasodilatory shock [15]. In this 
study, patients receiving a stable dose of vasopressor 
were treated with a starting dose of 20  ng  kg−1  min−1 
angiotensin II that could be adjusted every 5  min to 
achieve a MAP of ≥ 75 mmHg by hour 3. By 30  min, 
the angiotensin II dose had been down-titrated from 
20 to ≤ 5 ng kg−1 min−1 for 79 of 163 (48%) patients in 
the treatment arm; analyses comparing this population 
with those with a dose of > 5  ng  kg−1  min−1 at 30  min 
were prespecified. In a study by Fliser et  al. [16], dos-
ing with 1.5  ng  kg−1  min−1 of angiotensin II resulted 
in serum levels of ~ 50  pg/mL, just beyond the upper 
physiologic range for angiotensin II; therefore, admin-
istration of 1.5 to 5  ng  kg−1  min−1 angiotensin II is 
expected to result in serum levels of angiotensin II that 
approximate physiologic levels in a normotensive indi-
vidual [16, 17]. Doses of > 5 ng kg−1 min−1 are expected 
to result in serum levels in the pharmacologic range 
[16–18].
We hypothesized that patients most responsive to angi-
otensin II may have had a defect in angiotensin-convert-
ing enzyme function resulting in diminished angiotensin 
II levels. We further hypothesized that these low angio-
tensin II levels could be easily corrected to normal physi-
ologic levels by direct exogenous supplementation with 
the low dose of angiotensin II.
To further characterize the clinical benefit of angioten-
sin II and to explore these hypotheses, we compared vari-
ous efficacy and safety parameters in patients receiving 
angiotensin II in ATHOS-3 who were down-titrated to 
doses ≤ 5 ng kg−1 min−1 angiotensin II at 30 min versus 




Complete details of the ATHOS-3 study (registered Jan-
uary 2015, https ://clini caltr ials.gov/ct2/show/NCT02 
33884 3; principal investigator: George Tidmarsh) have 
been previously reported [15]. Briefly, ATHOS-3 was 
a placebo-controlled study that evaluated the safety 
and efficacy of angiotensin II as an addition to back-
ground vasopressor therapy in patients with catechola-
mine-resistant vasodilatory shock. Randomization was 
stratified according to MAP at screening (< 65  mmHg 
vs. ≥ 65  mmHg) and Acute Physiology and Chronic 
Health Evaluation II (APACHE II) score (≤ 30, 31 to 40, 
vs. ≥ 41) on a scale of 0 to 71, with higher scores indicat-
ing greater disease severity.
This registrational study was sponsored by La Jolla 
Pharmaceutical Company, was conducted under a special 
protocol agreement with the US Food and Drug Admin-
istration, and was approved by the appropriate national 
authorities and local research ethics boards. The study 
was conducted in accordance with current Good Clini-
cal Practice Guidelines, applicable local regulations, and 
the ethical principles described in the Declaration of 
Helsinki.
Patients
ATHOS-3 enrolled adult patients (aged ≥ 18  years) 
with vasodilatory shock, defined as central venous 
oxygen saturation > 70% with central venous pres-
sure > 8  mmHg or cardiac index > 2.3  L  min−1  m2, with 
catecholamine-resistant hypotension (patients receiv-
ing > 0.2 µg kg−1 min−1 of norepinephrine or norepineph-
rine-equivalent dose for 6 to 48 h prior to enrollment to 
maintain a MAP of 55 to 70 mmHg) after adequate fluid 
resuscitation.
Treatment
Enrolled and consented patients were randomly assigned 
to angiotensin II or saline placebo. The starting dose 
of angiotensin II was 20  ng  kg−1  min−1 and could be 
adjusted every 5 min to achieve a MAP of ≥ 75 mmHg by 
hour 3. The maximum permitted dose of angiotensin II 
from hour 0 to 3 was 200 ng kg−1 min−1. Standard-of-care 
vasopressors were held constant unless increases were 
proscribed for safety reasons. From hours 3 to 48, dose of 
study drug could be adjusted to 1.25 to 40 ng kg−1 min−1 
to maintain a MAP of 65 to 70  mmHg, and standard-
of-care vasopressors could be down-titrated. There was 
a protocol-mandated down-titration of angiotensin II 
at hour 48. If, upon discontinuation, the subjects’ car-
diovascular (CV) Sequential Organ Failure Assessment 
(SOFA) score was 4, the investigator could restart treat-
ment. During this treatment phase, the dose adjustment 
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criteria remained the same as previously. Angiotensin 
II was down-titrated gradually, by ≤ 10  ng  kg−1  min−1 
every 15 min, when being discontinued and standard-of-
care vasopressors were titrated according to institutional 
protocols. The protocol-specified maximum duration of 
angiotensin use was 7 days.
Outcomes
Efficacy outcomes included the proportion of patients 
who achieved a MAP response at hour 3, change in nor-
epinephrine-equivalent dose from baseline, mortality 
to day 28, and safety. The MAP response at hour 3 was 
defined as achieving ≥ 75  mmHg or an increase of ≥ 10 
mmHg from baseline at hour 3 without an increase in 
standard-of-care vasopressors prior to hour 3.
Statistical methods
The difference in outcomes based on angiotensin II dose 
at 30  min was a prespecified analysis. No patients dis-
continued treatment prior to 30 min, and all 163 patients 
receiving angiotensin II were included.
The association of angiotensin II dose with efficacy 
parameters was evaluated using univariate and multivari-
ate analyses to adjust for potential imbalances between 
the two dose groups. Time-to-event endpoints including 
all-cause survival were summarized using Kaplan–Meier 
estimates, and unadjusted group comparisons were 
conducted using the log-rank test. Multivariate time-
to-event analyses were conducted using proportional 
hazards modeling. Binary outcomes (e.g., hour 3 MAP 
responders) were analyzed by chi-square test for unad-
justed analyses and by logistic regression for multivariate 
analyses.
For multivariate analyses, the following dichotomized 
baseline covariates were adjusted for age ≥ 65  years, 
sex, MAP < 65  mmHg, APACHE II score > 30, albu-
min level < 2.5  g/dL, Model for End-Stage Liver Disease 
score ≥ 30, chest radiograph finding of acute respiratory 
distress syndrome (ARDS), and norepinephrine-equiva-
lent dose ≥ 0.5  μg  kg−1  min−1. Additional analyses were 
conducted, including baseline angiotensin I less than 
median and angiotensin II less than median.
Results
Baseline demographic and disease characteristics
Of the 163 patients who were randomly assigned to 
receive angiotensin II, 79 patients (48.5%) were receiv-
ing ≤ 5  ng  kg−1  min−1 angiotensin II at 30  min, and 84 
patients (51.5%) were receiving > 5 ng kg−1 min−1 angio-
tensin II at 30  min. Baseline demographic and disease 
characteristics of these 2 subgroups are shown in Table 1. 
In general, patients whose angiotensin II dose had been 
down-titrated at 30  min to ≤ 5  ng  kg−1  min−1 were 
more likely to have a higher baseline MAP (P < 0.0001) 
and a lower baseline norepinephrine-equivalent dose 
(P = 0.0049). Patients in the ≤ 5  ng  kg−1  min−1 angio-
tensin II subgroup were also more likely to have lower 
endogenous levels of angiotensin I (P = 0.0058) and angi-
otensin II (P = 0.0009) at baseline (Table 1).
Efficacy in angiotensin II dose groups
MAP response at hour 3
A significantly higher proportion of patients receiv-
ing ≤ 5 ng kg−1 min−1 angiotensin II at 30 min achieved 
a MAP response at hour 3 (≥ 75 mmHg or ≥ 10  mmHg 
increase in MAP) compared with patients requir-
ing > 5  ng  kg−1  min−1 angiotensin II at 30  min (89.9% 
[95% CI 81.0–95.5%] vs. 51.2% [95% CI 40.0–62.3%], 
respectively; unadjusted odds ratio, 8.46 [95% CI 3.63–
19.74]; P < 0.001; Fig. 1a). Univariate analyses within sub-
groups of patients showed a consistent trend for higher 
MAP response in patients receiving 5  ng  kg−1  min−1 
angiotensin II at 30 min. This included subgroups defined 
by the quartiles of baseline angiotensin II (measured in 
pg/mL). Statistically significant treatment benefits were 
largest in patients with lower baseline angiotensin II lev-
els (Fig.  1b). Multivariate analyses of MAP response at 
hour 3, adjusting for baseline disease covariates, were 
also significant for angiotensin II dose at 30  min (odds 
ratio, 9.09; 95% CI 3.53–23.4; P ≤ 0.0001).
Norepinephrine‑equivalent doses and SOFA score
Patients in the ≤ 5  ng  kg−1  min−1 angiotensin II sub-
group received lower norepinephrine-equivalent doses 
from hours 3 to 48 (mean [SD] dose 0.16 ng kg−1 min−1 
[0.242]) than patients in the > 5 ng kg−1 min−1 angioten-
sin II subgroup (0.51 ng kg−1 min−1 [0.750]). At hour 48, 
41 of 79 (52%) patients in the ≤ 5 ng kg−1 min−1 angioten-
sin II subgroup had discontinued all other vasopressors 
versus 25 of 84 (30%) patients in the > 5  ng  kg−1  min−1 
subgroup. Early sensitivity to angiotensin II was also 
associated with a significantly greater improvement in 
total SOFA score and CV SOFA score from screening to 
hour 48 (Table 2).
Survival at day 28
Survival at day 28 was 67% (95% CI 56–76%) in patients 
down-titrated to ≤ 5  ng  kg−1  min−1 angiotensin II at 
30 min compared with 41% (95% CI 31–52%) in patients 
who received > 5 ng kg−1 min−1 angiotensin II at 30 min 
(relative risk, 0.45; 95% CI 0.28–0.72; P = 0.0007; 
Fig. 2). Univariate analyses within subgroups of patients 
showed a consistent trend for higher day 28 survival in 
patients receiving ≤ 5  ng  kg−1  min−1 angiotensin II at 
30  min. For example, survival was significantly higher 
for patients receiving ≤ 5  ng  kg−1  min−1 angiotensin 
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Table 1 Baseline disease and demographic characteristics in analysis population
Angiotensin II > 5 ng kg−1 min−1 (n = 84) Angiotensin 
II ≤ 5 ng kg−1 min−1 
(n = 79)
Age, n (%)
 < 65 years 47 (56.0) 43 (54.4)
 ≥ 65 years 37 (44.0) 36 (45.6)
Sex, n (%)
 Male 47 (56.0) 45 (57.0)
 Female 37 (44.0) 34 (43.0)
Race, n (%)
 White 69 (82.1) 66 (83.5)
 Nonwhite 15 (17.9) 13 (16.5)
Body mass index, n (%) n = 83 n = 78
 < 18.5 kg/m2 3 (3.6) 4 (5.1)
 ≥ 18.5 to < 25 kg/m2 22 (26.5) 21 (26.9)
 ≥ 25 to < 30 kg/m2 20 (24.1) 22 (28.2)
 ≥ 30 kg/m2 38 (45.8) 31 (39.7)
Geographic region, n (%)
 Australia/New Zealand 17 (20.2) 11 (13.9)
 Europe 10 (11.9) 9 (11.4)
 USA/Canada 57 (67.9) 59 (74.7)
Albumin, n (%) n = 78 n = 76
 < 2.5 g/dL 56 (71.8) 47 (61.8)
 ≥ 2.5 g/dL 22 (28.2) 29 (38.2)
Cause of shock, n (%)
 Sepsis 68 (81.0) 59 (74.7)
 Likely sepsis 8 (9.5) 12 (15.2)
 Vasoplegia 3 (3.6) 7 (8.9)
 Other 5 (6.0) 1 (1.3)
Baseline MAP,* n (%)
 < 65 mmHg 37 (44.0) 15 (19.0)
 ≥ 65 mmHg 47 (56.0) 64 (81.0)
Baseline APACHE II score, n (%)
 ≤ 30 54 (64.3) 51 (64.6)
 31–40 29 (34.5) 21 (26.6)
 ≥ 41 1 (1.2) 7 (8.9)
Norepinephrine-equivalent dose 6 h before randomization, mean, µg/kg/min 
(SD)
0.52 (0.301) 0.45 (0.377)
Baseline norepinephrine-equivalent dose,* n (%)
 < 0.5 µg/kg/min 50 (59.5) 67 (84.8)
 ≥ 0.5 µg/kg/min 34 (40.5) 12 (15.2)
Baseline angiotensin I,* n (%) n = 74 n = 71
 Mean (SD) 678.9 (810.8) 618.0 (1332.5)
 Median (range) 346.0 (10.5–3730.0) 164 (10.5–9180.0)
  < 72.3 pg/mL 12 (16.2) 24 (33.8)
 72.3 to < 253 pg/mL 14 (18.9) 19 (26.8)
 253 to < 676 pg/mL 25 (33.8) 14 (19.7)
  ≥ 676 pg/mL 23 (31.1) 14 (19.7)
Baseline angiotensin II,* n (%) n = 74 n = 70
 Mean (SD) 420.8 (680.3) 128.3 (199.1)
 Median (range) 157.5 (10.5–3340.0) 61.3 (10.5–1090.0)
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II regardless of baseline MAP (MAP ≤ 65  mmHg vs. 
MAP > 65  mmHg) (Table  3). In patient subsets defined 
by quartiles of baseline angiotensin I or II levels, a higher 
proportion of patients treated with ≤ 5  ng  kg−1  min−1 
angiotensin II were alive at day 28 than patients receiv-
ing > 5  ng  kg−1  min−1 angiotensin II. In multivariate 
analyses to account for imbalances between dose groups, 
patients treated with ≤ 5  ng  kg−1  min−1 angiotensin 
II were significantly more likely to survive than those 
receiving > 5  ng  kg−1  min−1 (relative risk, 0.53; 95% CI 
0.32–0.86; P = 0.011).
Treatment exposure and safety in angiotensin II dose 
groups
In otherwise healthy patients, the plasma concentration 
of angiotensin II is ~ 5 to 35  pg/mL [19]. In the criti-
cally ill patients with distributive shock studied herein, 
the mean serum concentration of angiotensin II in 
the > 5 ng kg−1 min−1 angiotensin II subgroup was 420.8 
(± 680.4) pg/mL at baseline and in the ≤ 5 ng kg−1 min−1 
angiotensin II subgroup was 128.3 (± 199.1) pg/mL at 
baseline. Survival was significantly higher for patients 
in the ≤ 5  ng  kg−1  min−1 angiotensin II subgroup with 
relatively low baseline angiotensin II levels (< 23.85  pg/
mL) (Table 3).
Patients receiving > 5  ng  kg−1  min−1 angiotensin II at 
30 min were more likely to have serious adverse events, 
moderate to severe adverse events, or adverse events 
resulting in discontinuation, compared with patients 
receiving ≤ 5  ng  kg−1  min−1 angiotensin II at 30  min 
(Table  4). The most commonly reported treatment-
emergent adverse events (reported in > 10% of patients 
in either dosing subgroup) included septic shock, atrial 
fibrillation, multiorgan failure, hypotension, thrombocy-
topenia, and hypokalemia (Additional file 1: Table S1).
Discussion
Seventy-nine of 163 (48%) patients were down-titrated 
from an initial angiotensin II dose of 20  ng  kg−1  min−1 
to a dose of ≤ 5 ng kg−1 min−1 at 30 min following initia-
tion of study drug. This subset of patients was more likely 
to have a MAP response, increased 28-day survival, and 
better safety profile when considering grade 3/4 and seri-
ous AEs. These data may provide health care practition-
ers an early indication of which patients are most likely to 
respond to angiotensin II.
Table 1 (continued)
Angiotensin II > 5 ng kg−1 min−1 (n = 84) Angiotensin 
II ≤ 5 ng kg−1 min−1 
(n = 79)
 < 23.85 pg/mL 14 (18.9) 21 (30.0)
 23.85 to < 83.75 pg/mL 11 (14.9) 21 (30.0)
 83.75 to < 299.5 pg/mL 25 (33.8) 21 (30.0)
 ≥ 299.5 pg/mL 24 (32.4) 7 (10.0)
Exposure to angiotensin-converting enzyme inhibitors 7 (8.3) 8 (10.1)
Exposure to angiotensin II receptor blockers 9 (10.7) 2 (2.5)
Radiographic finding of ARDS 23 (27.4) 17 (21.5)
Cardiac index (L/min/m2) n = 36 n = 33
 Mean (SD) 3.5 (1.07) 3.1 (0.73)
 Median (range) 3.1 (2.3–6.4) 3.0 (2.1–5.4)
ScvO2 (%) n = 59 n = 61
 Mean (SD) 78.2 (8.14) 77 (9.64)
 Median (range) 79.0 (53–99) 75.9 (45–99)
Central venous pressure (mmHg) n = 64 n = 62
 Mean (SD) 14.3 (5.8) 13.2 (4.1)
 Median (range) 13.0 (5–35) 12.0 (6–29)
SOFA score
 Mean (SD) 12.0 (2.8) 11.5 (2.8)
 Median (range) 12.0 (5–18) 12.0 (5–18)
ARDS, acute respiratory distress syndrome; MAP, mean arterial pressure;  ScvO2, central venous oxygen saturation; SD, standard deviation; SOFA, Sequential Organ 
Failure Assessment
All n’s are as in the table header, unless otherwise specified
Exposure to angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers within week prior to starting study
*Statistically significant, P < 0.01
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P = 0.0010 >5 ng kg
−1 min−1
≤5 ng kg−1 min−1 
Fig. 1 Proportion of patients who had a MAP response at hour 3 by their angiotensin II dose, at 30 min following study initiation; > 5 ng kg−1 min−1 
versus ≤ 5 ng kg−1 min−1 (a). Proportion of patients who had a MAP response at hour 3 by their angiotensin II dose at 30 min and quartiles of 
baseline angiotensin II (b). CI, confidence interval; MAP, mean arterial pressure
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Patients in the ≤ 5  ng  kg−1  min−1 angiotensin II sub-
group had lower levels of endogenous baseline angio-
tensin II than their counterparts in the > 5 ng kg−1 min−1 
angiotensin II subgroup. However, the angiotensin II 
levels for patients with shock are higher than those for 
normal patients as previous studies have shown levels of 
angiotensin II in normal adult plasma to range from 5 to 
35 pg/mL [19]. The observations seen herein support our 
hypothesis that patients sensitive to low levels of angio-
tensin II (≤ 5 ng kg−1 min−1) are more likely to have an 
angiotensin II insufficiency. Nonetheless, supplemen-
tation with exogenous angiotensin II in “angiotensin II 
insufficient” patients helped rapidly restore MAP and 
was associated with improved outcomes. The possible 
reasons underlying sensitivity to exogenous angiotensin 
II remain unclear, as patients in the ≤ 5  ng  kg−1  min−1 
subgroup had lower baseline angiotensin II levels but 
also had higher baseline MAP and lower norepineph-
rine-equivalent doses at baseline. In addition, no differ-
ence existed between the > 5  ng  kg−1  min−1 angiotensin 
II subgroup and the ≤ 5  ng  kg−1  min−1 angiotensin II 
subgroup in characteristics potentially associated with 
impaired production/function of angiotensin II (such as 
prior use of angiotensin-converting enzyme inhibitors, 
use of angiotensin II receptor blockers, or radiographic 
evidence of ARDS; Table 1). It is conceivable that angio-
tensin II sensitivity is linked to endothelial injury, which 
was not rigorously assessed in the current analyses or 
the ATHOS-3 study. Across the entire cohort, the deliv-
ered dose of exogenous angiotensin II would overcome 
any inherent angiotensin-converting enzyme defects, 
so it is likely that attenuation of the MAP response to 
angiotensin II in the > 5 ng kg−1 min−1 subgroup may be 
influenced by other factors, including down-regulation 
of angiotensin I/II receptors in conditions such as sep-
sis and/or biofeedback to the production of vasodila-
tory peptides [20–22]. Although our analysis does not 
Table 2 Change from  screening to  hour 48 in  total SOFA 
score and CV SOFA score
CV, cardiovascular; MAP, mean arterial pressure; SOFA, Sequential Organ Failure 
Assessment; SD, standard deviation
a van Elteren Wilcoxon rank test of angiotensin II dose at 30 min stratified by 
randomization strata for MAP and APACHE II score
b All patients had a CV SOFA score of 4 (highest risk) at screening based 
on inclusion/exclusion criteria. For patients missing a 48-hour assessment, 
the last observation was carried forward. In the event of death prior to the 
48-hour assessment, the patient was assigned a CV SOFA score of 4. The van 
Elteren Wilcoxon rank test compared angiotensin II with placebo adjusting for 
randomization strata for MAP and APACHE II score
Angiotensin 
II > 5 ng kg−1 min−1 
(n = 84)
Angiotensin 




 Mean (SD) 2.6 (5.5) − 0.6 (5.0) 0.002a
 Median (range) 1.0 (− 6 to 15) − 2.0 (− 10 to 15)
CV SOFA  scoreb
 Mean (SD) − 1.33 (1.7) − 2.2 (1.7) 0.004
 Median (range) 0.0 (− 4 to 0) − 3.0 (–4 to 0)
79 78 75 72 69 68 68 64 62 61 57 57 56 55 55 55 55 54 54 54 54 54 54 54 54 53 395565















Time From Randomization, days
0 1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24
Angiotensin II dose at 30 mins:
     ≤5 ng kg−1 min−1
     >5 ng kg−1 min−1
25 26 27 28187
≤5 ng kg−1 min−1
Patients at risk, n:















≤5 ng kg−1 min−1
>5 ng kg−1 min−1
Fig. 2 Proportion of patients surviving at day 28 by their angiotensin II dose, at 30 min following study initiation; > 5 ng kg−1 min−1 
versus ≤ 5 ng kg−1 min−1. CI, confidence interval
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account for all possible mechanisms that could account 
for the differences in MAP response between the two 
subgroups, patients receiving ≤ 5  ng  kg−1  min−1 angio-
tensin II at 30 min represent a subset of patients who may 
be more likely to safely recover from shock and who can 
be identified soon after treatment initiation (at 30 min). 
This observation may allow clinicians to rapidly identify 
those patients who may benefit most from the continued 
use of angiotensin II.
Those patients who required ≤ 5  ng  kg−1  min−1 at 
30  min had less severe shock (higher baseline MAP) 
and lower baseline norepinephrine-equivalent doses 
than those who required > 5 ng kg−1 min−1. Accordingly, 
the beneficial effect seen in these patients may support 
the concept of using angiotensin II earlier in the course 
of disease. Additionally, in prespecified analyses, these 
patients exhibited improved survival even after adjusting 
for baseline differences in shock. Again, this would sug-
gest that the use of angiotensin II at an early stage may 
be reasonable before a patient progresses to more severe 
refractory shock at very high norepinephrine-equivalent 
doses.
The study has several limitations. First, even though 
this was a prespecified analysis, the subgroups were 
defined by an on-treatment variable that was likely to be 
related to drug efficacy and was associated with better 
prognostic characteristics, not all of which are measured 
and controllable. However, no patients were discontin-
ued from treatment within 30 min, nor was there selec-
tion bias, as all patients receiving angiotensin II were 
included in the analyses. The on-treatment variable of 
angiotensin II dose was adjusted based on MAP respon-
siveness, so higher hour 3 response rates in patients who 
ultimately required lower hour 3 doses of angiotensin 
II were expected. However, dose adjustment was made 
based on prespecified, objective, and easily measurable 
criteria (i.e., MAP), adding validity to the study findings. 
The observed improvement in day 28 survival in patients 
Table 3 Univariate analysis of survival at day 28 for baseline covariates significantly different between the angiotensin II 
dose groups
CI, confidence interval; MAP, mean arterial pressure
*Hazard ratio/log-rank test result of treatment effect within subgroup






 ≥ 65 mmHg 47, 44.7 (30.2–58.1) 64, 67.2 (54.2–77.2) 0.52 (0.29–0.92) 0.023
 < 65 mmHg 37, 37.4 (22.1–52.7) 15, 66.7 (37.5–84.6) 0.38 (0.14–1.00) 0.041
Baseline norepinephrine-equivalent dose
 < 0.5 µg kg−1 min−1 50, 47.4 (33.0–60.5) 67, 68.7 (56.1–78.3) 0.53 (0.30–0.95) 0.030
 ≥ 0.5 µg kg−1 min−1 34, 32.4 (17.6–48.0) 12, 58.3 (27.0–80.1) 0.45 (0.17–1.19) 0.100
Baseline angiotensin I
 < 72.3 pg/mL 12, 41.7 (15.2–66.5) 24, 66.7 (44.3–81.7) 0.49 (0.18–1.35) 0.160
 72.3 to < 253 pg/mL 14, 42.9 (17.7–66.0) 19, 57.9 (33.2–76.3) 0.56 (0.21–1.48) 0.234
 253 to < 676 pg/mL 25, 39.3 (20.5–57.6) 14, 85.7 (53.9–96.2) 0.18 (0.04–0.80) 0.011
 ≥ 676 pg/mL 23, 52.2 (30.5–70.0) 14, 50.0 (22.9–72.2) 1.02 (0.40–2.64) 0.962
Baseline angiotensin II
 < 23.85 pg/mL 14, 28.6 (8.8–52.4) 21, 71.4 (47.2–86.0) 0.29 (0.10–0.80) 0.011
 23.85 to < 83.75 pg/mL 11, 36.4 (11.2–62.7) 21, 71.4 (47.2–86.0) 0.37 (0.12–1.09) 0.060
 83.75 to < 299.5 pg/mL 25, 43.2 (23.5–61.5) 21, 57.1 (33.8–74.9) 0.64 (0.27–1.47) 0.285
 ≥ 299.5 pg/mL 24, 58.3 (36.4–75.0) 7, 57.1 (17.2–83.7) 1.01 (0.28–3.66) 0.993
Table 4 Summary of  treatment-emergent adverse events 
(regardless of causality) in either dosing subgroup
Angiotensin 
II > 5 ng kg−1 min−1 
(n = 84)
Angiotensin 
II ≤ 5 ng kg−1 min−1 
(n = 79)
Any grade, n (%) 76 (90.5) 66 (83.5)
Grade 3/4, n (%) 64 (76.2) 43 (54.4)
Serious adverse events, 
n (%)
64 (76.2) 35 (44.3)
Adverse events resulting 
in discontinuation, 
n (%)
19 (22.6) 4 (5.1)
Fatal adverse events, 
n (%)
0 1 (1.3)
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receiving ≤ 5  ng  kg−1  min−1 of angiotensin II is not 
directly linked to angiotensin II dose, but it is expected 
that patients with better prognostic characteristics may 
be more likely to demonstrate immediate responsive-
ness. As a result, there were significant imbalances 
in key disease and previous treatment characteristics 
between the two groups that confound the interpreta-
tion of these analyses. For example, patients receiv-
ing ≤ 5  ng  kg−1  min−1 angiotensin II had significantly 
lower baseline norepinephrine-equivalent dose and sig-
nificantly higher baseline MAP compared with patients 
in the subgroup receiving > 5 ng kg−1 min−1. To account 
for the baseline differences, we performed regression 
analyses adjusting for the baseline characteristics. How-
ever, there may be unmeasured characteristics that were 
unaccounted for.
Conclusions
Despite these limitations, this prespecified analysis of 
ATHOS-3 showed that, for a significant proportion of 
patients with vasodilatory shock, a low dose of angio-
tensin II may be effective and is safe, and may provide 
an early indication of which patients are more likely to 
respond to angiotensin II. Larger, prospective studies are 
needed to understand the reasons underlying the phe-
nomenon of hyper-responsiveness to low doses of angio-
tensin II and to identify all responders. Such information 
would be informative for clinical decision-making as well 
as help improve emergency management of patients with 
vasodilatory shock.
Additional file
Additional file 1: Table S1. Summary of Treatment-Emergent Adverse 
Events (regardless of causality) Reported in >5% of Patients in Either Dos-
ing Subgroup.
Abbreviations
APACHE II: Acute Physiology and Chronic Health Evaluation II; ARDS: acute 
respiratory distress syndrome; ATHOS-3: Angiotensin II for the Treatment of 
High-Output Shock; CI: confidence interval; MAP: mean arterial pressure; SD: 
standard deviation; SOFA: Sequential Organ Failure Assessment.
Acknowledgements
Medical writing and editorial assistance was provided by Jerome Sah, PhD, of 
ApotheCom, Yardley, PA, USA. This assistance was funded by La Jolla Pharma-
ceutical Company, San Diego, CA, USA.
Authors’ contributions
KRH, DWB, MTM, and LWB helped interpret the results of the analyses and 
were major contributors in writing of the manuscript. RF, MNG, AKK, SNC, and 
MO were major contributors in providing interpretation of the data. FZ, LSC, 
and GFT were involved in the acquisition and analysis of the data. All authors 
read and approved the final manuscript and have agreed to be accountable 
for the work. All authors read and approved the final manuscript.
Funding
These analyses and the original study were funded by La Jolla Pharmaceutical 
Company.
Availability of data and material
The datasets used and analyzed during the current analyses are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The ATHOS-3 study was approved by the appropriate national authorities and 
local research ethics boards. The study was conducted in accordance with the 
current Good Clinical Practice Guidelines, applicable local regulations, and 




KRH reports no conflict of interest. DWB received consulting payment from La 
Jolla Pharmaceutical Company and received grant/payment to his institu-
tion from La Jolla Pharmaceutical Company. MTM is on the speakers bureau 
for La Jolla Pharmaceutical Company, and his institution received a grant for 
its role as a participating site in the ATHOS-3 trial. LWB reports payment for 
consulting work from La Jolla Pharmaceutical Company. RF reports nothing to 
disclose. MNG reports payment to her institution for the conduct of the trials 
in the form of a contract to perform the study. AKK reports payment from La 
Jolla Pharmaceutical Company for consulting work and participation in the 
company’s speakers bureau. SNC reports nothing to disclose. LSC and GFT are 
employees of La Jolla Pharmaceutical Company. MO and FZ report nothing to 
disclose.
Author details
1 Division of Critical Care Medicine, Regions Hospital, University of Minnesota, 
640 Jackson Street, St. Paul, MN 55101, USA. 2 Division of Critical Care, Depart-
ment of Anesthesiology, University of California, Los Angeles, Los Angeles, CA, 
USA. 3 Department of Medicine, University of Maryland School of Medicine, 
Baltimore, MD, USA. 4 Department of Medicine, Emory University, Atlanta, GA, 
USA. 5 Critical Care Center, CHU Lille, Lille, France. 6 Lille Inflammation Research 
Center, University of Lille School of Medicine, Lille, France. 7 Department 
of Medicine, Montefiore Healthcare Center, Albert Einstein College of Medi-
cine, Bronx, NY, USA. 8 Department of Anesthesiology, Section on Critical Care 
Medicine, Wake Forest School of Medicine, Winston-Salem, NC & Outcomes 
Research Consortium, Cleveland, OH, USA. 9 Department of Surgery, Sunrise 
Hospital, Las Vegas, NV, USA. 10 La Jolla Pharmaceutical Company, San Diego, 
CA, USA. 11 Department of Critical Care, Guy’s and St. Thomas Hospital, King’s 
College London, London, UK. 
Received: 5 April 2019   Accepted: 20 May 2019
References
 1. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 
2013;369:1726–34.
 2. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for 
the treatment of septic shock: systematic review and meta-analysis. PLoS 
ONE. 2015;10:e0129305.
 3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, 
Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally 
ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman 
CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno 
R. Surviving Sepsis Campaign: international guidelines for manage-
ment of severe sepsis and septic shock, 2012. Intensive Care Med. 
2013;39:165–228.
 4. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Bras-
seur A, Defrance P, Gottignies P, Vincent JL, Investigators SI. Comparison 
of dopamine and norepinephrine in the treatment of shock. N Engl J 
Med. 2010;362:779–89.
 5. Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-
and-Hyde conundrum. Intensive Care Med. 2016;42:1387–97.
Page 10 of 10Ham et al. Ann. Intensive Care            (2019) 9:63 
 6. Hessler M, Arnemann PH, Seidel L, Kampmeier T, Rehberg S, Ertmer C. 
ATHOS-3 and the knights of the round table–the search for the holy grail 
of vasopressors. J Thorac Dis. 2017;9:2788–91.
 7. Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser 
MW. Adverse cardiac events during catecholamine vasopressor therapy: a 
prospective observational study. Intensive Care Med. 2012;38:950–8.
 8. Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox 
M. Potentially inadvertent immunomodulation: norepinephrine use in 
sepsis. Am J Respir Crit Care Med. 2016;194:550–8.
 9. Yamamura H, Kawazoe Y, Miyamoto K, Yamamoto T, Ohta Y, Morimoto 
T. Effect of norepinephrine dosage on mortality in patients with septic 
shock. J Intensive Care. 2018;6:12.
 10. Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, Meys-
signac B, Vigne C, Zieleskiewicz L, Leone M. Norepinephrine: not too 
much, too long. Shock. 2015;44:305–9.
 11. Sacha GL, Lam SW, Duggal A, Torbic H, Bass SN, Welch SC, Butler RS, Bauer 
SR. Predictors of response to fixed-dose vasopressin in adult patients with 
septic shock. Ann Intensive Care. 2018;8:35.
 12. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose 
vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.
 13. Correa TD, Takala J, Jakob SM. Angiotensin II in septic shock. Crit Care. 
2015;19:98.
 14. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, 
Seneff MG. Intravenous angiotensin II for the treatment of high-output 
shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534.
 15. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, 
Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock 
S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong 
MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bel-
lomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM. ATHOS-3 
investigators: angiotensin II for the treatment of vasodilatory shock. N 
Engl J Med. 2017;377:419–30.
 16. Fliser D, Arnold U, Kohl B, Hartung R, Ritz E. Angiotensin II enhances 
insulin sensitivity in healthy volunteers under euglycemic conditions. J 
Hypertens. 1993;11:983–8.
 17. Wolf RL, Mendlowitz M, Gitlow SE, Naftchi N. Metabolism of angiotensin 
II-I-131 in normotensive and hypertensive human subjects. Circulation. 
1961;23:754–8.
 18. Fliser D, Dikow R, Demukaj S, Ritz E. Opposing effects of angiotensin II 
on muscle and renal blood flow under euglycemic conditions. J Am Soc 
Nephrol. 2000;11:2001–6.
 19. Dusterdieck G, McElwee G. Estimation of angiotensin II concentration in 
human plasma by radioimmunoassay. Some applications to physiological 
and clinical states. Eur J Clin Invest. 1971;2:32–8.
 20. Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent down-regulation 
of angiotensin II type 2 receptors during experimental sepsis. Crit Care 
Med. 2001;29:1750–5.
 21. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregula-
tion of angiotensin II type 1 receptors during sepsis. Hypertension. 
2001;38:177–82.
 22. Chawla LS, Chen S, Bellomo R, Tidmarsh GF. Angiotensin converting 
enzyme defects in shock: implications for future therapy. Crit Care. 
2018;22(1):274.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
